Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes

Southern Medical Journal

Volumn 92, Issue 4, 1999, Pages 415-416

  Sartor, Oliver ^a   Eastham, James A ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; MEGESTROL ACETATE;

AGED; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER HORMONE THERAPY; CASE REPORT; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; HOT FLUSH; HUMAN; MALE; PATHOPHYSIOLOGY; PROSTATE CANCER;

EID: 0032950552     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199904000-00013     Document Type: Article

References (11)

1. Oesterling JE, Moyad MA: The ABCs of Prostate Cancer: The Book That Could Save Your Life. Lanham, Md, Madison Books, 1997, p 154
2. Smith JA Jr: A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. J Urol 1994; 152:132-134
3. Loprinzi CL, Michalak JC, Quella SK, et al: Megestrol acetate for prevention of hot flashes. N Engl J Med 1994; 331:347-352
4. Quella S, Loprinzi CL, Sloan J, et al: Long-term use of megestrol-acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82:1784-1788
5. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:1566-1572
6. Schellhammer PF, Venner P, Haas GP, et al: Prostate-specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157:1731-1735
7. Bissada R, Kaczmerek AT: Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 1995; 153:1944-1945
8. Dawson NA, McLeod DG: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of antiandrogen withdrawal syndrome. J Urol 1995; 153:1946-1947
9. Veldscholte J, Ris-Stalpers C, Kuipper GGJM, et al: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990; 173:534-540
10. Culig Z, Hobisch A, Cronauer MV, et al: Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 12:1541-1550
11. Taplin ME, Bubley GJ, Shuster TD, et al: Androgen receptor mutations in metastatic androgen independent prostate cancer. N Engl J Med 1995; 332:1393-1398